Resolution of the Council of Excperts (16th June, 2022): Therapy of gouty arthritis with an IL-1 inhibitor (anakinra)

<jats:p>.</jats:p>

[1]  M. Eliseev,et al.  Use of anakinra in treatment of combination of calcium pyrophosphate deposition desease and gout (clinical observation) , 2022, Medical alphabet.

[2]  O. Boyman,et al.  Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders , 2022, Frontiers in Immunology.

[3]  H. Rezaei,et al.  Current evidence on the use of anakinra in COVID-19 , 2022, International Immunopharmacology.

[4]  E. Nasonov,et al.  The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist) , 2022, Rheumatology Science and Practice.

[5]  R. Giacomelli,et al.  Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. , 2021, Clinical and experimental rheumatology.

[6]  P. Libby,et al.  Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. , 2020, Journal of the American College of Cardiology.

[7]  G. Guyatt,et al.  Author's response to Letter. , 2020, Arthritis care & research.

[8]  P. Guggenbuhl,et al.  Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. , 2019, Rheumatology.

[9]  C. van Durme,et al.  Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. , 2019, Rheumatology.

[10]  P. Dieudé,et al.  Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. , 2018, Joint, bone, spine : revue du rhumatisme.

[11]  C. Dinarello.  Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.

[12]  Michael U. Martin,et al.  The family of the interleukin‐1 receptors , 2018, Immunological reviews.

[13]  I. Peene,et al.  Anakinra in resistant gout: a case report , 2017, Acta clinica Belgica.

[14]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[15]  Е. Л. Насонов,et al.  Роль интерлейкина 1 в развитии заболеваний человека , 2016, RSP 2016.

[16]  E. Gertner,et al.  Anakinra for the treatment of acute severe gout in critically ill patients. , 2015, Seminars in arthritis and rheumatism.

[17]  A. Aouba,et al.  Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature , 2015, Mediators of inflammation.

[18]  M. Galeazzi,et al.  Anakinra treatment in patients with gout and type 2 diabetes , 2015, Clinical Rheumatology.

[19]  J. Holst,et al.  The interleukin‐1 receptor antagonist anakinra improves first‐phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance , 2014, Diabetes, obesity & metabolism.

[20]  M. S. Eliseev,et al.  Канакинумаб (ингибитор интерлейкина 1β) — прорыв в возможностях противовоспалительной терапии при подагре , 2013 .

[21]  M. Dougados,et al.  Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases , 2013, Arthritis Research & Therapy.

[22]  G. Gardner,et al.  Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra , 2013, Arthritis care & research.

[23]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[24]  Y. Carmi,et al.  IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation , 2011, The Journal of Immunology.

[25]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[26]  C. Mancuso,et al.  Anakinra's efficacy is variable in refractory gout: report of ten cases. , 2010, Seminars in arthritis and rheumatism.

[27]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[28]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[29]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.